Agastan Bio Cheme Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 29-12-2024
- Paid Up Capital ₹ 0.50 M
as on 29-12-2024
- Company Age 21 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 27.69%
(FY 2022)
- Profit 50.19%
(FY 2022)
- Ebitda 47.27%
(FY 2022)
- Net Worth 44.42%
(FY 2022)
- Total Assets 18.59%
(FY 2022)
About Agastan Bio Cheme
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Buragadda Rao and Clarence Dsouza serve as directors at the Company.
- CIN/LLPIN
U24117TG2003PTC040450
- Company No.
040450
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Feb 2003
- Date of AGM
20 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Agastan Bio Cheme Private Limited offer?
Agastan Bio Cheme Private Limited offers a wide range of products and services, including Cardiovascular Drugs & Medication, Kidney Drugs, Organic and Inorganic Solvents, Alcohol Solvents, Research and Development (R&D) Work, Product Development Research, Flavours & Aromatics, Natural Sweetener, Glycerine, Refined Glycerine.
Who are the key members and board of directors at Agastan Bio Cheme?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Buragadda Rao  | Director | 10-Apr-2019 | Current |
| Clarence Dsouza | Director | 31-May-2019 | Current |
Financial Performance of Agastan Bio Cheme.
Agastan Bio Cheme Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 27.69% increase. The company also saw a substantial improvement in profitability, with a 50.19% increase in profit. The company's net worth Soared by an impressive increase of 44.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Agastan Bio Cheme?
In 2019, Agastan Bio Cheme had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Agastan Bio Cheme?
Unlock and access historical data on people associated with Agastan Bio Cheme, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Agastan Bio Cheme, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Agastan Bio Cheme's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
